Inside This Issue  by unknown
NOVEMBER 19/26, 2013
VOLUME 62, NO. 21
JOURNAL of the AMERICAN COLLEGE of CARDIOLOGYInside This Issue
STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSStent Thrombosis 1915
Tullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, Andrea Mariani,
Philippe Genereux, Angelo Branzi, Gregg W. Stone
First-generation drug-eluting stents (DES) that impart controlled release of sirolimus or
paclitaxel have been shown to reduce the risk of restenosis and target vessel revascularization
compared with bare-metal stents (BMS). However, stent thrombosis (ST) emerged as a
major safety concern. Second-generation DES have been developed to overcome this issue
with improved stent design and use of biocompatible and bioabsorbable polymers. In this
state-of-the-art paper, Palmerini and colleagues analyze the relative risk of ST, death, and
myocardial infarction of ﬁrst-generation DES, second-generation DES, and BMS. They also
discuss the mechanism of reduced ST with second-generation DES.STATE-OF-THE-ART PAPERSDiastolic Dysfunction in Valvular Heart Disease 1922
Rasheed R. Zaid, Colin M. Barker, Stephen H. Little, Sherif F. Nagueh
In this state-of-the-art paper, Zaid and colleagues discuss the mechanisms behind pre- and
post-operative diastolic dysfunction in patients with aortic and mitral valve disease. The
diagnostic aspects of diastolic dysfunction in these patients and the implications for treatment
are also discussed.(continued on page A-34)
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Frederick A. Masoudi, Angelo Ponirakis, Robert W. Yeh, Thomas M. Maddox, Jim Beachy,
Paul N. Casale, Jeptha P. Curtis, James De Lemos, Gregg Fonarow, Paul Heidenreich,
Christina Koutras, Mark Kremers, John Messenger, Issam Moussa, William J. Oetgen,
Matthew T. Roe, Kenneth Rosenﬁeld, Thomas S. Shields, Jr., John A. Spertus, Jessica Wei,
Christopher White, Christopher H. Young, John S. Rumsfeld
The National Cardiovascular Data Registry (NCDR) is comprised of 7 quality measurement
and improvement programs. In this paper, Masoudi and colleagues provide a description and
overview of the patient population, participating centers, and patterns of care from the
5 NCDR programs for which comprehensive data from 2011 is available.CLINICAL RESEARCH CORONARY ARTERY DISEASECarotid Revascularization and Open Heart Surgery 1948
Mehdi H. Shishehbor, Sridhar Venkatachalam, Zhiyuan Sun, Jeevanantham Rajeswaran,
Samir R. Kapadia, Christopher Bajzer, Heather L. Gornik, Bruce H. Gray, John R. Bartholomew,
Daniel G. Clair, Joseph F. Sabik, III, Eugene H. Blackstone
The best approach to manage coexisting severe carotid and coronary disease remains
uncertain. Current treatment options include staged carotid endarterectomy (CEA) followed
by open heart surgery (OHS), combined CEA and OHS, or staged carotid artery stenting
(CAS). The objective of this study was to compare the risk-adjusted outcomes of these
3 approaches. The primary composite endpoint was all-cause death, stroke, and myocardial
infarction (MI). A total of 350 patients who underwent carotid revascularization within
90 days prior to OHS were evaluated. Propensity analysis revealed staged CAS-OHS and
combined CEA-OHS had similar early hazard phase composite outcomes, whereas CEA-
OHS incurred the highest risk driven by inter-stage MI. Subsequently, staged CAS-OHS
experienced signiﬁcantly fewer late hazard phase events in comparison with both staged and
combined CEA-OHS. Shishehbor and colleagues conclude that staged CAS-OHS and
combined CEA-OHS are associated with a similar risk of death, stroke, or MI in the short
term, and both approaches were superior to staged CEA-OHS. However, outcomes favor
staged CAS-OHS after the ﬁrst year.
Editorial Comment: Ehtisham Mahmud, Ryan Reeves, p. 1957(continued on page A-35)
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Mohamed B. Elshazly, Seth S. Martin, Michael J. Blaha, Parag H. Joshi, Peter P. Toth,
John W. McEvoy, Mohammed A. Al-Hijji, Krishnaji R. Kulkarni, Peter O. Kwiterovich,
Roger S. Blumenthal, Steven R. Jones
The justiﬁcation for present guideline-based non–high-density lipoprotein cholesterol
(HDL-C) cutpoints that are 30 mg/dl higher than low-density lipoprotein cholesterol
(LDL-C) cutpoints remains largely untested. The objective of this study was to examine
patient-level discordance between population percentile of non–HDL-C and LDL-C.
Population percentiles were assigned to non–HDL-C and Friedewald-estimated LDL-C
values of 1,310,440 adults with triglyceride levels <400 mg/dl. Results showed that LDL-C
cutpoints of 70, 100, 130, 160, and 190 mg/dl were in the same population percentile as
non–HDL-C values of 93, 125, 157, 190, and 223 mg/dl. Non–HDL-C reclassiﬁed a
signiﬁcant portion of patients within a higher treatment category compared with Friedewald
LDL-C. Of patients with LDL-C <70 mg/dl, 15% had a non–HDL-C 100 mg/dl
(guideline-based cutpoint) and 25% had non-HDL-C 93 mg/dl (percentile-based
cutpoint). Elshazly and colleagues conclude that there is signiﬁcant patient-level discordance
between non–HDL-C and LDL-C percentiles at lower LDL-C and higher triglyceride
levels. Current non–HDL-C cutpoints for high-risk patients may need to be lowered to
match percentiles of LDL-C cutpoints.(continued on page A-38)
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Michael V. Holmes, Tabassome Simon, Holly J. Exeter, Lasse Folkersen, Folkert W. Asselbergs,
Montse Guardiola, Jackie A. Cooper, Jutta Palmen, Jaroslav A. Hubacek, Kathryn F. Carruthers,
Benjamin D. Horne, Kimberly D. Brunisholz, Jessica L. Mega, Erik P. A. van Iperen, Mingyao Li,
Maarten Leusink, Stella Trompet, Jeffrey J. W. Verschuren, G. Kees Hovingh, Abbas Dehghan,
Christopher P. Nelson, Salma Kotti, Nicolas Danchin, Markus Scholz, Christiane L. Haase,
Dietrich Rothenbacher, Daniel I. Swerdlow, Karoline B. Kuchenbaecker, Eleonora Staines-Urias,
Anuj Goel, Ferdinand van ’t Hooft, Karl Gertow, Ulf de Faire, Andrie G. Panayiotou, Elena Tremoli,
Damiano Baldassarre, Fabrizio Veglia, Lesca M. Holdt, Frank Beutner, Ron T. Gansevoort,
Gerjan J. Navis, Irene Mateo Leach, Lutz P. Breitling, Hermann Brenner, Joachim Thiery,
Dhayana Dallmeier, Anders Franco-Cereceda, Jolanda M. A. Boer, Jeffrey W. Stephens,
Marten H. Hofker, Alain Tedgui, Albert Hofman, André G. Uitterlinden, Vera Adamkova, Jan Pitha,
N. Charlotte Onland-Moret, Maarten J. Cramer, Hendrik M. Nathoe, Wilko Spiering, Olaf H. Klungel,
Meena Kumari, Peter H. Whincup, David A. Morrow, Peter S. Braund, Alistair S. Hall,
Anders G. Olsson, Pieter A. Doevendans, Mieke D. Trip, Martin D. Tobin, Anders Hamsten,
Hugh Watkins, Wolfgang Koenig, Andrew N. Nicolaides, Daniel Teupser, Ian N. M. Day,
John F. Carlquist, Tom R. Gaunt, Ian Ford, Naveed Sattar, Sotirios Tsimikas, Gregory G. Schwartz,
Debbie A. Lawlor, Richard W. Morris, Manjinder S. Sandhu, Rudolf Poledne,
Anke H. Maitland-van der Zee, Kay-Tee Khaw, Brendan J. Keating, Pim van der Harst, Jackie F. Price,
Shamir R. Mehta, Salim Yusuf, Jaqueline C. M. Witteman, Oscar H. Franco, J. Wouter Jukema,
Peter de Knijff, Anne Tybjaerg-Hansen, Daniel J. Rader, Martin Farrall, Nilesh J. Samani,
Mika Kivimaki, Keith A. A. Fox, Steve E. Humphries, Jeffrey L. Anderson, S. Matthijs Boekholdt,
Tom M. Palmer, Per Eriksson, Guillaume Paré, Aroon D. Hingorani, Marc S. Sabatine, Ziad Mallat,
Juan P. Casas, Philippa J. Talmud
Higher circulating levels of secretory phospholipase A2-(sPLA2)-IIA mass or sPLA2 enzyme
activity has been associated with increased risk of cardiovascular events. However, it is not
clear if this association is casual. In this study, Holmes and colleagues investigate the role of
sPLA2-IIA in cardiovascular disease. A Mendelian randomization meta-analysis of
19 general population studies and 10 acute coronary syndrome cohorts using rs11573156,
a variant in PLA2G2A encoding the sPLA2-11A isoenzyme, as a variable, was conducted.
Results revealed that the PLA2G2A rs11573156 C allele was associated with lower
circulating sPLA2-11A mass (38% to 44%) and sPLA2 enzyme activity (3% to 23%) per
C allele. However, there was no association among incident, prevalent, or major vascular
events. As a result, reducing sPLA2-IIA mass is unlikely to be a useful therapeutic goal for
preventing cardiovascular events.(continued on page A-39)
NOVEMBER 19/26, 2013 (continued) A-39HEART FAILUREHeart Rate Reduction Unloads the Left Ventricle 1977
Jan-Christian Reil, Jean-Claude Tardif, Ian Ford, Suzanne M. Lloyd, Eileen O’Meara,
Michel Komajda, Jeffrey S. Borer, Luigi Tavazzi, Karl Swedberg, Michael Böhm
The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart
derived from the pressure–volume relationship. Heart rate modulates Ea and, thereby,
afterload burden. The aim of this study was to determine whether isolated heart rate
reduction with ivabradine reduces afterload of patients with systolic heart failure. A total of
275 patients (n¼ 132 with placebo, n¼ 143 with ivabradine 7.5 mg) in the echocardiographic
substudy of the SHIFT (Systolic Heart failure treatment with I[F] inhibitor ivabradine Trial)
were studied. After treatment, heart rate was signiﬁcantly reduced in the ivabradine group,
accompanied by marked reduction in Ea and improved total arterial compliance compared
with placebo. Although contractility remained unchanged, ventricular–arterial coupling was
improved, resulting in higher stroke volume in the ivabradine-treated patients. Reil and
colleagues conclude that isolated heart rate reduction by ivabradine improved total arterial
compliance, thus reducing Ea. Because Ea is unaltered, improved ventricular coupling is
responsible for increased stroke volume.
Editorial Comment: Barry A. Borlaug, p. 1986HEART RHYTHM DISORDERSAF and Silent Cerebral Ischemia 1990Fiorenzo Gaita, Laura Corsinovi, Matteo Anselmino, Cristina Raimondo, Martina Pianelli,
Elisabetta Toso, Laura Bergamasco, Carlo Boffano, Maria Consuelo Valentini, Federico Cesarani,
Marco Scaglione
The objective of this study was to compare the prevalence of silent cerebral ischemia (SCI)
and cognitive performance in paroxysmal and persistent atrial ﬁbrillation (AF) patients as
compared with controls. A total of 180 patients with AF (50% paroxysmal and
50% persistent) and 90 controls in sinus rhythm were studied. Cognitive function was
evaluated and magnetic resonance imaging studies were obtained. At least 1 SCI was present
in 80 (89%) patients with paroxysmal AF, in 83 (92%) patients with persistent AF, and in
41 (46%) controls. Cognitive performance was signiﬁcantly worse in persistent and
paroxysmal AF patients than controls. Gaita and colleagues conclude that paroxysmal and
persistent AF patients have a higher prevalence and number of SCI per patient and a worse
cognitive performance than controls.
Editorial Comment: Steven Shea, Marco Di Tullio, p. 1998(continued on page A-40)
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Andrew E. Epstein, William T. Abraham, Nicole R. Bianco, Karl B. Kern, Michael Mirro,
Sunil V. Rao, Edward K. Rhee, Scott D. Solomon, Steven Szymkiewicz
In patients with left ventricular (LV) dysfunction post-acute myocardial infarction (MI),
current guidelines recommend use of an implantable cardioverter-deﬁbrillator after a waiting
period of 40 days or 3 months, respectively, depending on whether the patient was or was not
revascularized. This study assesses the characteristics and outcomes of patients who had a
wearable cardioverter-deﬁbrillator (WCD) prescribed during this waiting period. A total of
8,453 patients (age 62.7  12.7 years, 73% male) with acute MI and ejection fraction (EF)
35% were studied. Of these, 133 (1.6%) patients received 309 appropriate shocks (91% for
ventricular arrhythmia). For shocked patients, LVEF was 30% in 106 patients, 30% to 35%
in 17 patients, >36% in 8 patients, and not reported in 2 patients. Of treated patients, 75%
received treatment in the ﬁrst month and 96% within ﬁrst 3 months of use. Shock success
resulting in survival was 84% in nonrevascularized and 95% in revascularized patients.
Epstein and colleagues conclude that during the 40-day and 3-month waiting periods in
patients post-MI, the WCD successfully treated sudden cardiac arrest in 1.4%, with risk
being highest in the ﬁrst month of WCD use.
Editorial Comment: Paul C. Zei, p. 2008GENETICS/GENOMICSRole of Junctophilin in AF 2010
David L. Beavers, Wei Wang, Sameer Ather, Niels Voigt, Alejandro Garbino, Sayali S. Dixit,
Andrew P. Landstrom, Na Li, Qiongling Wang, Iacopo Olivotto, Dobromir Dobrev,
Michael J. Ackerman, Xander H. T. Wehrens
The objective of this study was to analyze the role of junctophilin-2 (JPH2) in atrial
ﬁbrillation (AF). JPH2 is believed to have an important role in sarcoplasmic reticulum (SR)
Ca2+ channels handling and in the modulation of ryanodine receptor Ca2+ channel (RyR2). A
novel, hypertrophic cardiomyopathy-associated JPH2 mutation, E169K, was identiﬁed in
2 patients with juvenile-onset paroxysmal atrial ﬁbrillation (pAF). Pseudo-knockin (PKI)
mouse models were generated to determine the molecular defects underlying the development
of AF caused by this mutation. Results revealed that PKI mice expressing E169K mutant
JPH2 exhibited a higher incidence of inducible AF compared with wild-type PKI mice.
E169K-PKI atrial cardiomyocytes showed an increased incidence of abnormal SR Ca2+
release events attributed to reduced binding of E169K-JPH2 to RyR2. Patients with PAF
had reduced atrial JPH2 levels per RyR2 channel compared with sinus rhythm patients and
had increased frequency of spontaneous Ca2+ release events. The results of the study
suggest a novel mechanism by which reduced JPH2-mediated stabilization of RyR2 due to
loss-of-function mutation or reduced JPH2/RyR2 ratio can promote SR Ca2+ leak and
atrial arrhythmias.
Editorial Comment: Joseph A. Hill, Abhinav Diwan, p. 2020
